EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients

Christophe Masset, Clarisse Kerleau, Gilles Blancho, Maryvonne Hourmant, Alexandre Walencik, Simon Ville, Delphine Kervella, Diego Cantarovich, Aurélie Houzet, Magali Giral, Claire Garandeau, Jacques Dantal und 1 weitere

Transplant International · 2023

DOI: 10.3389/ti.2023.10816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2023. Verfasst von Christophe Masset und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Kidney Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The choice between Basiliximab (BSX) or Anti-Thymocyte Globulin (ATG) as induction therapy in non-immunized kidney transplant recipients remains uncertain. Whilst ATG may allow steroid withdrawal and a decrease in tacrolimus, it also increases infectious complications. We investigated outcomes in non-immunized patients receiving a very low dosage of ATG versus BSX as induction. Study outcomes were patient/graft survival, cumulative probabilities of biopsy proven acute rejection (BPAR), infectious episode including CMV and post-transplant diabetes (PTD). Cox, logistic or linear statistical models were used depending on the studied outcome and models were weighted on propensity scores. 100 patients received ATG (mean total dose of 2.0 mg/kg) and 83 received BSX. Maintenance therapy was comparable. Patient and graft survival did not differ between groups, nor did infectious complications. There was a trend for a higher occurrence of a first BPAR in the BSX group (HR at 1.92; 95%CI: [0.77; 4.78]; p = 0.15) with a significantly higher BPAR episodes (17% vs 7.3%, p = 0.01). PTD occurrence was significantly higher in the BSX group (HR at 2.44; 95%CI: [1.09; 5.46]; p = 0.03). Induction with a very low dose of ATG in non-immunized recipients was safe and associated with a lower rate of BPAR and PTD without increasing infectious complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumKidney TransplantationHumansBasiliximabImmunosuppressive AgentsAntibodies, MonoclonalRetrospective StudiesGraft RejectionGraft SurvivalTransplant Recipients

Stichwörter der Autor:innen

diabetes mellitusinduction therapylow dose thymoglobulinlow immunological riskrejection

Substanzen

BasiliximabAntilymphocyte SerumImmunosuppressive AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France.
  • INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, Nantes, France.
  • Etablissement Francais du Sang, HLA Laboratory, Loos Nantes, France.

Zitieren

APA

Masset, C., Kerleau, C., Blancho, G., Hourmant, M., Walencik, A., Ville, S., Kervella, D., Cantarovich, D., Houzet, A., Giral, M., Garandeau, C., Dantal, J., & Nantes DIVAT Consortium (2023). Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients. Transplant International. https://doi.org/10.3389/ti.2023.10816

Vancouver

Masset C, Kerleau C, Blancho G, Hourmant M, Walencik A, Ville S, et al. Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients. Transplant International. 2023. doi:10.3389/ti.2023.10816

BibTeX
@article{Masset2023,
  author = {Masset, Christophe and Kerleau, Clarisse and Blancho, Gilles and Hourmant, Maryvonne and Walencik, Alexandre and Ville, Simon and Kervella, Delphine and Cantarovich, Diego and Houzet, Aurélie and Giral, Magali and Garandeau, Claire and Dantal, Jacques and Nantes DIVAT Consortium, Nantes DIVAT Consortium},
  title = {Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients},
  journal = {Transplant International},
  year = {2023},
  doi = {10.3389/ti.2023.10816}
}
Kostenlos starten →